title: A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
abstract: BACKGROUND
  The main objective of this randomized, double-blind, parallel-group, comparative study was to assess the efficacy and safety of rupatadine 10 mg (R10) and 20 mg (R20) administered once-daily for two weeks compared with those of loratadine 10 mg (L10) in the treatment of seasonal allergic rhinitis (SAR).
  
  
  METHODS
  A total of 339 SAR patients were randomized to receive R20 (111 patients), R10 (112 patients) or L10 (116 patients). The main efficacy variable was the mean total daily symptom score (mTDSS) based on the daily subjective assessment of the severity of rhinitis symptoms--rhinorrhea, sneezing, nasal itching, nasal obstruction, conjunctival itching, tearing and pharyngeal itching--recorded by patients.
  
  
  RESULTS
  The mTDSS was significantly lower in the groups treated with R20 (0.80 +/- 0.46) and R10 (0.85 +/- 0.52) than in the group treated with L10 (0.92 +/- 0.51) by protocol analysis (p = 0.03) but not by intention-to-treat analysis. The secondary variables used to assess efficacy (mDSS, DSSmax, CSS and TCSS) also showed significantly milder symptoms in patients treated with R20 and R10, particularly in sneezing and nasal itching. All treatments were well tolerated and no serious adverse events were recorded. Headache was the most frequent non-serious adverse event, and these did not show significant differences between treatments at similar dose levels. Somnolence was more frequent in R20 than in the other two groups.
  
  
  CONCLUSIONS
  The present results suggest that rupatadine 10 mg a day may be a valuable and safe alternative for the symptomatic treatment of seasonal allergic rhinitis.
authors.affiliation: Clinical Research Unit, Research Centre, J. Uriach & Cía S.A., Barcelona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Saint-Martin
authors.forename: J P
authors.initials: JP
authors.lastname: Dumur
authors.forename: I
authors.initials: I
authors.lastname: Pérez
authors.forename: I
authors.initials: I
authors.lastname: Izquierdo
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D018592:Cross-Over Studies; D003533:Cyproheptadine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D017336:Loratadine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D011336:Probability; D012016:Reference Values; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D006634:Histamine H1 Antagonists; D010972:Platelet Activating Factor; C103639:rupatadine; D003533:Cyproheptadine; D017336:Loratadine